In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report), ...

LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, ...

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial ...

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

Cindy Yao joined one of the country’s leading Asian food service product providers to lead it out of a difficult past and ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Young nearsighted kids who wear bifocal contact lenses that slow uncoordinated eye growth do not lose the benefits of the treatment once they stop wearing the lenses, new research shows.